The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module

  1. Bryan Goodwin,
  2. Ecushla Hodgson and
  3. Christopher Liddle
  1. Department of Clinical Pharmacology and Storr Liver Unit, University of Sydney at Westmead Hospital, Westmead, Australia

    Abstract

    Cytochrome P-450 3A4 (CYP3A4), the predominant cytochrome P-450 expressed in adult human liver, is subject to transcriptional induction by a variety of structurally unrelated xenobiotics, including the antibiotic rifampicin. The molecular mechanisms underlying this phenomenon are poorly understood. We transfected a human liver-derived cell line (HepG2) with various CYP3A4-luciferase reporter gene constructs containing a nested set of 5′-deletions of theCYP3A4 5′-flanking region. Rifampicin-inducible transcription of the reporter gene was observed only with the longest construct, which encompassed bases −13000 to +53 ofCYP3A4 (3-fold induction). The responsive region was functional regardless of its position or orientation relative to the proximal promoter of CYP3A4 and was capable of conferring rifampicin-inducible expression on a heterologous promoter. Further deletion mutants localized the induction to bases −7836 to −7607. In vitro DNase I footprint analysis of this region revealed four protected sites (FP1, FP2, FP3, and FP4). Two of these sites, FP3 (bases −7738 to −7715) and FP4 (bases −7698 to −7682), overlapped binding motifs for the orphan human pregnane X receptor (hPXR). Cotransfection of responsive constructs with a hPXR expression vector substantially increased the rifampicin-inducibility to ∼50-fold. In addition, the rifampicin-responsive constructs were strongly activated by a range of CYP3A inducers. Finally, we demonstrate cooperativity between elements within the distal enhancer region andcis-acting elements in the proximal promoter ofCYP3A4. Our results provide evidence for the existence of a potent enhancer module, 8 kb distal to the transcription start point, which mediates the transcriptional induction ofCYP3A4 by activators of hPXR.

    Footnotes

    • Send reprint requests to: Dr. Christopher Liddle, Department of Clinical Pharmacology and Storr Liver Unit, University of Sydney at Westmead Hospital, Westmead, NSW 2145, Australia. E-mail: chrisl{at}westgate.wh.usyd.edu.au

    • This work was supported by a grant from the National Health and Medical Research Council (Australia) and the Robert W. Storr bequest to the Medical Foundation, University of Sydney. B.G. was a recipient of the National Health and Medical Research Council (Australia) Dora Lush Biomedical Scholarship.

    • 1 Three independent studies have implicated an orphan nuclear receptor in CYP3A regulation. The human PXR (hPXR; Lehmann et al., 1998) and human pregnane activated receptor (hPAR; Bertilsson et al., 1998) are identical in the derived amino acid sequence. The human steroid and xenobiotic receptor (hSXR; Blumberg et al., 1998) contains a single base-pair insertion at position 1225 and a single base deletion at 1279, relative to hPXR, which results in a shift in the reading frame for amino acid residues 215–233. However, hPXR, hPAR, and hSXR almost certainly represent products of the same gene. In this study, we used the “hPXR” nomenclature.

    • Abbreviations:
      P-450
      cytochrome P-450
      PXR
      pregnane X receptor
      RXRα
      9-cis retinoic acid receptor-α
      PXRE
      pregnane X receptor response element
      prPXRE
      proximal pregnane X receptor response element
      HNF
      hepatocyte nuclear factor
      EMSA
      electrophoretic mobility shift assay
      RORα1
      retinoic acid receptor-related receptor α-1
      COUP-TF
      chicken ovalbumin upstream promoter-transcription factor
      PCR
      polymerase chain reaction
      PCN
      pregnenolone 16α-carbonitrile
      tk
      herpes simplex virus thymidine kinase
      hGR
      human glucocorticoid receptor
      GRE
      glucocorticoid-responsive element
      XREM
      xenobiotic-responsive enhancer module
      DMSO
      dimethyl sulfoxide
      • Received July 6, 1999.
      • Accepted August 26, 1999.
    « Previous | Next Article »Table of Contents